The $6.6 million increase was due to a $4.1 million increase for personnel costs related to our continued preparation for the commercial launch of dalbavancin, which occurred in July 2014, an increase of $1.8 million for consultancy related to commercial planning activities and an increase of $0.5 million for occupancy and other operating expenses.